Edgewise Therapeutics reports Q1 2022 net loss of $14.7M; cash at $265.8M

Edgewise Therapeutics, Inc.

2022-Q1 EPS reported -$0.30

Net loss of $14.7M ($0.30 per share) vs. $12.7M in the prior quarter.
Cash, equivalents and marketable securities of $265.8M; expected to fund operations through 2024.
Completed enrollment of ARCH open-label study of EDG-5506 in BMD; Phase 2 trials planned for 2022.
R&D expenses $11.1M, up $2.0M from prior quarter; G&A flat at $3.7M.
Advanced preclinical EDG-002 program targeting hypertrophic cardiomyopathy; IND-enabling studies in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.